These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19036061)

  • 41. Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
    Brugge JM; Tans G; Rosing J; Castoldi E
    Thromb Haemost; 2006 Feb; 95(2):236-42. PubMed ID: 16493484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
    Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC
    Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of decreased response to activated protein C during pregnancy by an endogenous thrombin potential-based assay.
    Sugimura M; Kobayashi T; Kanayama N; Terao T
    Semin Thromb Hemost; 1999; 25(5):497-502. PubMed ID: 10625209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
    Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
    Simkova M; Simko F; Kovacs L
    Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.
    Antovic A; Blombäck M; Bremme K; Van Rooijen M; He S
    J Thromb Haemost; 2003 Dec; 1(12):2531-5. PubMed ID: 14675088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
    Rühl H; Schröder L; Müller J; Sukhitashvili S; Welz J; Kuhn WC; Oldenburg J; Rudlowski C; Pötzsch B
    PLoS One; 2014; 9(8):e105007. PubMed ID: 25121606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
    Endrikat J; Noah M; Gerlinger C; Bannemerschult R; Junge W; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Oct; 64(4):217-22. PubMed ID: 11747870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
    Eichinger S; Weltermann A; Philipp K; Hafner E; Kaider A; Kittl EM; Brenner B; Mannhalter C; Lechner K; Kyrle PA
    Thromb Haemost; 1999 Oct; 82(4):1232-6. PubMed ID: 10544904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages.
    Mahjoub T; Mtiraoui N; Tamim H; Hizem S; Finan RR; Nsiri B; Almawi WY
    Am J Hematol; 2005 Sep; 80(1):12-9. PubMed ID: 16138341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
    Nojima J; Iwatani Y; Ichihara K; Tsuneoka H; Ishikawa T; Yanagihara M; Takano T; Hidaka Y
    Thromb Res; 2009 May; 124(1):127-31. PubMed ID: 19128822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
    Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
    Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA
    Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.
    Noordermeer T; Chemlal S; Jansma JJ; van der Vegte V; Schutgens REG; Limper M; de Groot PG; Meijers JCM; Urbanus RT
    J Thromb Haemost; 2023 Sep; 21(9):2509-2518. PubMed ID: 37290588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women.
    Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
    J Pregnancy; 2011; 2011():232840. PubMed ID: 21869933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Congenital and acquired activated protein C resistance.
    Nicolaes GA; Dahlbäck B
    Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.